These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32684582)

  • 1. [COMPLETE RESPONSE OF BULKY LYMPH NODE METASTASES TREATED WITH ENZALUTAMIDE AFTER CHEMOTHERAPY WITH DOCETAXEL IN CASTRATION-RESISTANT PROSTATE CANCER: A CASE REPORT].
    Ishii T; Ide T; Miyajima T; Tominaga K; Miyajima S; Taira H; Haraoka S
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(3):201-205. PubMed ID: 32684582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant reduction in burden of metastatic disease by intermittent docetaxel therapy in a patient with castration-resistant prostate cancer.
    Kirisawa T; Nakamura E; Okuno T; Hagimoto H; Matsuda A; Shinoda Y; Komiyama M; Fujimoto H; Matsui Y
    Int Cancer Conf J; 2024 Apr; 13(2):98-102. PubMed ID: 38524658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate Cancer Detected by Choroidal Tumor and Complete Response to Hormonal Therapy: Case Report and Literature Review of 24 Patients With Choroidal Metastasis From Prostate Cancer.
    Matsuo T; Tanaka T; Nakamura A; Wada K
    J Investig Med High Impact Case Rep; 2021; 9():23247096211026471. PubMed ID: 34159819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.
    Raddin RS; Walko CM; Whang YE
    Anticancer Drugs; 2011 Mar; 22(3):299-302. PubMed ID: 21360851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostate cancer of unknown primary origin with multiple lymph nodes metastasis; a case report].
    Haraoka M; Takamuki M; Toyonaga Y; Tanaka M; Hanazawa K; Sakamoto Y; Horie S
    Nihon Hinyokika Gakkai Zasshi; 2014 Oct; 105(4):212-7. PubMed ID: 25757353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
    Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
    Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports].
    Kobayashi S; Tsukamoto T; Tohsaka A; Tohma T
    Hinyokika Kiyo; 2008 Jun; 54(6):423-6. PubMed ID: 18634439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response to ethnylestradiol prolonged for almost two years in patients with castration-resistant prostate cancer.
    Hongo H; Kosaka T; Oya M
    Can Urol Assoc J; 2014 Nov; 8(11-12):E921-3. PubMed ID: 25553169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
    Kusukawa N; Ishida H; Tanase K; Ito H; Aoki Y; Ooyama N; Akino H; Yokoyama O
    Hinyokika Kiyo; 2013 May; 59(5):301-4. PubMed ID: 23719139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leptomeningeal Metastases in a Patient with Castration-Resistant Prostate Cancer.
    Koie T; Hashimoto Y; Suzuki Y; Hatayama Y; Kimura F
    Case Rep Urol; 2020; 2020():5627548. PubMed ID: 33005471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
    van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
    Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Delay in High-Grade Metastatic Prostate Cancer Progression by Dutasteride : A Case Report].
    Yamada Y; Fujiwara H; Somiya S; Fujikawa S; Kamiyama Y; Tamaki M; Kanaoka T
    Hinyokika Kiyo; 2018 Apr; 64(4):187-192. PubMed ID: 29772622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A CASE OF CASTRATION-RESISTANT PROSTATE CANCER THAT COMPLETELY AMELIORATED AFTER TRANSITION TO BEST SUPPORTIVE CARE].
    Kise H
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):113-116. PubMed ID: 35444080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
    Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
    BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate adenocarcinoma with negative immunohistochemical stain of prostate-specific antigen presenting with cervical mass: A case report.
    Zhu L; Luo C; Wu W; Ying J; Zhong H
    J Res Med Sci; 2013 Sep; 18(9):814-7. PubMed ID: 24381627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report.
    Fujiwara R; Kageyama S; Tomita K; Hanada E; Tsuru T; Yoshida T; Narita M; Isono T; Kawauchi A
    Case Rep Oncol; 2015; 8(2):339-44. PubMed ID: 26351443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.